[en] BACKGROUND: The homozygous deletion of Pkd1 in the mouse results in embryonic lethality with renal cysts and hydrops fetalis, but there is no precise data on the segmental origin of cysts and potential changes associated with polyhydramnios. METHODS: We used Pkd1-null mice to investigate cystogenesis and analyze the amniotic fluid composition from embryonic day 12.5 (E12.5) to birth (n = 257 embryos). RESULTS: Polyhydramnios was consistently observed from E13.5 in Pkd1(-/-) embryos, in absence of placental abnormalities but with a significantly higher excretion of sodium and glucose from E13.5 through E16.5, and increased cyclic adenosine 3'5-monophosphate (cAMP) levels at E14.5 and E15.5. The Pkd1(-/-) embryos started to die at E13.5, with lethality peaking at E15.5, corresponding to the onset of cystogenesis. The first cysts in Pkd1(-/-) kidneys emerged at E15.5 in mesenchyme-derived segments at the cortico-medullary junction, with a majority of glomerular cysts and fewer proximal tubule cysts (positive for megalin). The cysts extended to ureteric bud-derived collecting ducts (positive for Dolichos biflorus agglutinin lectin) from E16.5. CONCLUSIONS: These studies indicate that Pkd1 deletion is associated with a massive loss of solutes (from E13.5) and increased cAMP levels (E14.5) associated with polyhydramnios. These abnormalities precede renal cysts (E15.5), first derived from glomeruli and proximal tubules and later from the collecting ducts, reflecting the expression pattern of Pkd1 in maturing epithelial cells.
Pirson Y, Chauveau D, Devuyst O. Autosomal dominant polycystic kidney disease. Oxford Textbook of Clinical Nephrology. Oxford: Oxford University Press, 2005; 3rd Edition, 2304-2324
Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nature Clin Prac Neph 2006; 2: 40-55
Devuyst O, Beauwens R. Ion transport and cystogenesis: the paradigm of autosomal dominant polycystic kidney disease. Advances in Nephrology. St. Louis: Mosby, 1998; 28439-28478
Chauvet V, Qian F, Boute N, et al. Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Pathol 2002; 160: 973-983
Boulter C, Mulroy S, Webb S, et al. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci USA 2001; 98: 12174-12179
Lu W, Peissel B, Babakhanlou H, et al. Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet 1997; 17: 179-181
Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al. Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 2000; 97: 1731-1736
Lu W, Shen X, Pavlova A, et al. Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects. Hum Mol Genet 2001; 10: 2385-2396
Muto S, Aiba A, Saito Y, et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 2002; 11: 1731-1742
Nishio S, Hatano M, Nagata M, et al. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J Clin Invest 2005; 115: 910-918
Casal JA, Hermida J, Lens XM, et al. A comparative study of three kidney biomarker tests in autosomal dominant polycystic kidney disease. Kidney Int 2005; 68: 948-954
Allen E, Piontek KB, Garrett-Mayer E, et al. Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in mu-rine tissues via alterations in nuclear hormone receptors. Hum Mol Genet 2006; 15: 11-21
Ahrabi AK, Terryn S, Valenti G, et al. Pkd1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mouse. J Am Soc Nephrol 2007; 18: 1740-1753
Ibraghimov-Beskrovnaya O, Dackowski WR, Let F, et al. Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein. Proc Natl Acad Sci USA 1997; 94: 6397-6402
Halatek T, Hermans C, Broeckaert F, et al. Quantification of Clara cell protein in rat and mouse biological fluids using a sensitive im-munoassay. Eur Respir J 1998; 11: 726-733
Christensen EI, Brin H. Megalin and cubilin: multifunctional endo-cytic receptors. Nat Rev Mol Cell Biol 2002; 3: 256-266
Murata F, Tsuyama S, Suzuki S, et al. Distribution of glycoconjugates in the kidney studied by use of labelled lectins. J Histochem Cyto-chem 1983; 31: 139-144
Guillaume R, D'Agati V, Daoust M, et al. Murine Pkd1 is a develop-mentally regulated gene from morula to adulthood: role in tissue condensation and patterning. Dev Dyn 1999; 214: 337-348
Pritchard L, Sloane-Stanley JA, Sharpe JA, et al. A human PKD1 transgene generates functional polycystin-1 in mice and is associated with a cystic phenotype. Hum Mol Genet 2000; 9: 2617-2627
Thivierge C, Kurbegovic A, Couillard M, et al. Overexpression of PKD1 causes polycystic kidney disease. Mol Cell Biol 2006; 26: 1538-1548
Brace RA, Wolf EJ. Normal amniotic fluid volume changes throughout pregnancy. Am J Obstet Gynecol 1989; 161: 382-389
Cheung CY, Brace RA. Amniotic fluid volume and composition in mouse pregnancy. J Soc Gynecol Investig 2005; 12: 558-562
Kirshon B. Fetal urine in hydramnios. Obstet Gynecol 1989; 73: 240-242
Jouret F, Igarashi T, Gofflot F, et al. Comparative ontogeny, processing, and segmental distribution of the renal chloride channel, ClC-5. Kidney Int 2004; 65: 198-208
Loughna S, Landels E, Woolf AS. Growth factor control of developing kidney endothelial cells. Exp Nephrol 1996; 4: 112-118
Yuen BH, Wittmann B, Staley K. Cyclic adenosine 3', 5'-mono-phosphate (cAMP) in pregnancy body fluids during normal and abnormal pregnancy. Am J Obstet Gynecol 1976; 125: 597-602
Webster SK, Haramati A. Developmental changes in the phosphaturic response to parathyroid hormone in the rat. Am J Physiol 1985; 249: F251-F255
Gattone VH, Xiaofang W, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Medicine 2003; 9: 1323-1326
Torres VE, Xiaofang W, Qian Q, et al. Effective treatment of an ortho-logous model of autosomal dominant polycystic kidney disease. Nature Medicine 2004; 10: 363-364
Wang X, Gattone V 2nd, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16: 846-851
Magenheimer BS, St John PL, Isom KS, et al. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na+, K+, 2Cl-co-transporter-dependent cystic dilation. J Am Soc Nephrol 2006; 17: 3424-3437
Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1140-1150
Verani RR, Silva FG. Histogenesis of the renal cysts in adult (auto-somal dominant) polycystic kidney disease: a histochemical study. Mod Pathol 1988; 1: 457-463
Torra R, Badenas C, Darnell A, et al. Autosomal dominant poly-cystic kidney disease with anticipation and Caroli's disease associated with a PKD1 mutation. Kidney Int 1997; 52: 33-38
Devuyst O, Burrow CR, Smith BL, et al. Expression of aquaporins-1 and-2 during nephrogenesis and in autosomal dominant polycystic kidney disease. Am J Physiol 1996; 271: F169-F183